Niloofar Abolhasani Khaje is a PhD candidate in Pharmaceutical Sciences with an emphasis in Pharmacology from the University of Mississippi under Prof. Joshua Sharp’s supervision. She has a BSc in Chemical Engineering from Sharif University of Technology in Tehran, Iran. She is passionate about developing new mass spectrometry-based methods for studying the structure-function relationships of biomolecules. She has developed novel methods for data collection of Hydroxyl Radical Protein Footprinting (HRPF) via Fast Photochemical Oxidation of Proteins (FPOP) that allow for more efficient collection and analysis of the resulting data. She accomplished this by developing an LC-MS/MS method that allows coelution of isomeric oxidized peptides, which don’t coelute under standard Reverse Phase (RP) LC-MS/MS methods, while separating different peptides. She also demonstrated that the coeluted isomeric peptides could be accurately quantitated using data-dependent acquisition methods instead of the time consuming data-independent methods that have to be used with RP methods. In collaboration with other members of the Sharp lab and labs across the country, Niloofar is developing methods to transform HRPF-FPOP MS into a structural technique. This requires adapting current methods in computational modeling to use HRPF-FPOP data to allow for structure determination of biomolecules that would be difficult using the standard X-ray crystallography, NMR, and cryo-EM methods.

Am Mphil student reading Pharmaceutical microbiology. I find bacteria interesting and always looking at how mutations in bacteria can be countered by drugs, particularly crude medicine.

Am also open to challenges in different fields that seeks to leverage on my knowledge to improve the world

Norah Alghamdi is a clinical chemistry chief fellow at University of Louisville Hospital. She graduated from Cleveland State University with Ph.D. degree in Clinical Bio-Analytical Chemistry. Her clinical research interests focus on discovering biomarkers and developing rapid, accurate and cost-efficient diagnostic methods.

Dr. Ghaith Altawallbeh is a board-certified Clinical Chemist for Primary Children’s Hospital and Intermountain Central Laboratory. He is also an adjunct Assistant Professor of Pathology at the University of Utah Medical Center.

I am currently a clinical chemistry fellow at Johns Hopkins University School of Medicine. My clinical chemistry fellowship started at Vanderbilt University Medical Center before transitioning to JH. I received a B.S degree in Clinical Laboratory Sciences from the University of Nevada, Las Vegas where I began research in laboratory medicine and toxicology. Before returning to school to earn my PhD, I served as a medical laboratory scientist at Harborview Medical Center, University of Washington in Seattle, WA in the area of hematology and coagulation. My PhD is in Pharmacology and Toxicology from Michigan State University, where my research was on the adipose tissue's adrenergic control of vasoconstriction. I completed a research postdoctoral fellowship at Yale University in Laboratory Medicine, where I studied RNA-methylation mechanisms of hematopoietic malignancies and completed collaborative research projects in clinical chemistry at the Yale New Haven Hospital on procalcitonin utility and establishing reference intervals.

Rebecca holds a master’s degree in biomedical science is a doctoral candidate in the Clinical Bioanalytical Chemistry PhD program at Cleveland State University. Her research aims include the use of mass spectrometry-based proteomics applied to colorectal cancer research, including early onset disease, and uncovering prognostic markers of relapse. She also has developed a quantitative LC-MS/MS method to quantify inflammatory and immune-related stool proteins with the goal to better improve adenoma detection rates compared with current screening tests.
Prior to her joining her doctoral program, Rebecca had conducted research at MAP Sciences in the UK as a part of her master’s thesis work where she used MALDI-TOF MS for the early the detection of preeclampsia by mass spectral fingerprinting and for maternal antenatal screening of other gestational disorders.
Rebecca also hold a concurrent position at the Proteomics and Metabolomics Core at the Cleveland Clinic Lerner Research Institute, where she is responsible for untargeted metabolomics workflows and data analysis as well as targeted small molecule method development.
Rebecca’s academic training and research experience has provided her with a strong background in clinical biochemistry and informatics to investigate clinical problems using the latest technology in mass spectrometry-based proteomics and metabolomics.

BA Biochemistry at Columbia University
MD PhD University of California San Diego
5 years management consulting experience
Residency in clinical pathology at UCSD

I am Nazmin Bithi. I am from Bangladesh and graduated from the University of Asia Pacific with a Bachelor’s in Pharmacy. Currently, I am a 4th year Ph.D. student in the ComACC-accredited doctoral clinical chemistry program at Cleveland State University (CSU), doing my doctoral research at the Cleveland Clinic Lerner Research Institute. My Ph.D. research is focused on the determination of endogenous hydrogen sulfide in different tissue and tissue-specific sulfhydration (post-translational modification of protein) along with their biological function under 50% dietary restriction in aged and glioblastoma model by using mass spectrometry-based proteomics. I am the chair of the student engagement committee of the Lerner graduate student association. I am looking forward to becoming a clinical chemistry fellow after my Ph.D. completion next year spring.

I am a North West Cancer Research-funded PhD student in the Centre for Proteome Research, Institute of Systems, Molecular & Integrative Biology of the University of Liverpool, supervised by Professors Claire and Patrick Eyers. I hold a BSc in Chemistry and an MSc in Molecular Biomedicine from the University of Athens, Greece. My PhD research is focused on deciphering the cellular targets of tyrosine kinase inhibitors using mass spectrometry-based proteomics. Outside of the lab, I have a passion for science communication projects, and have worked as a science writer and web manager/editor.

I am a Bachelor of Science student (in Integrated Science) at McMaster University. I focus on interdisciplinary research, as well as the investigation of chemical biology as it pertains to healthcare.

I am a postdoctoral research associate investigating the neuropathological aspects of acute brain insults. I will be transitioning into a clinical chemistry fellowship in 2022.

B.S. in Analytical Chemistry, Masaryk University, Brno, Czech Republic.
Ph.D. in Bioanalytical Chemistry, Brigham Young University, Provo, Utah.
Nearly three decades of HPLC, CE, CE-MS, and LC-MSMS method development and validation experience in academic, pharmaceutical, and clinical laboratory environments.

Dr. Timothy Collier is Scientific Director of Lab Operations and Cardiology R&D for Quest Cardiometabolic Center of Excellence at Cleveland HeartLab, where his responsibilities include overseeing the identification and development of assays for cardiovascular biomarkers.

Steven E. Conklin Lopez received his B.S. in Chemistry (2013) from the University of Puerto Rico – Río Piedras Campus and completed his PhD training (2019) at Duke University under the mentorship of Prof. Katherine J. Franz. As a graduate student, his research focused on understanding the role of metals and metal coordination in the chemical and biological activity of antimicrobial peptides. Currently, he is a Clinical Chemistry Fellow in the Pathology Department of the Johns Hopkins University School of Medicine.

Colleen is a postdoctoral fellow position in the Interventional Radiology Department at UT MD Anderson and earned her PhD in Mechanical Engineering at the University of Michigan. As an undergraduate at the Georgia Institute of Technology, she began her research in cardiovascular health and thermoregulation. Her background in material science and biomedical engineering provide a unique approach to her research by combining engineering concepts and physiology. Colleen hopes to continue her research as a professor and inspire the next generation of scientists and researchers. Experience in research, teaching (2 semesters as a Graduate Student Instructor), and service (Rackham Student Government Vice President).

Demonstrated history of working in the higher education administration from Rackham Student Government leadership positions. Skilled in Image Analysis, Small Animal Research, Magnetic Resonance Imaging (MRI), Leadership, MATLAB, Data Analysis, Statistics, and Microsoft Excel/Powerpoint/Word.

I am Jeany Delafiori, PhD student at University of Campinas (UNICAMP) supervised by Prof. Dr. Rodrigo Ramos Catharino. We focus on untargeted metabolomics approaches to discover and investigate metabolites for clinical diagnosis, prognosis and pathophysiology of infectious diseases. I am currently working in the evaluation of prolonged infection of prostate cells with Zika virus and the metabolic profile of COVID-19 patients.

Christine Dolin is a clinical chemistry fellow at the University of Kentucky. She received her Ph.D. in Pharmacology and Toxicology from the University of Louisville in 2019. In her graduate research, she applied proteomics to identify novel drug targets and biomarkers for alcoholic liver disease. She looks forward to continuing to advance her knowledge of mass spectrometry and learn about its applications in the clinical laboratory. She hopes to apply mass spectrometry throughout her future career as a clinical chemist.

Erika Dorado is a postdoctoral researcher at Imperial College London working on lipidomic analysis and the identification of body-fluid based biomarkers for cancer diagnosis. She completed her PhD in Clinical Medicine Research at Imperial College London working on the lipidomic analysis of extracellular vesicles and its potential for cancer diagnosis. Before starting her PhD, she worked on proteomics and phosphoproteomics analysis in cancer signaling pathways at the Barts Cancer Institute. Her MSc was focused on -omics technologies, where she worked on analysis of protein-protein interactions using cross-linking mass spectrometry. She obtained her BSc in Biology focused in molecular and cell biology, and after that worked in the study of mutations in antimalarial and malaria diagnosis targets. She is one of the leads of the MSACL Early Career Network (MSACL ECN) and is currently the Chair of the European Region.

I received my PhD in bioanalytical chemistry from York University, Canada in 2008. After graduation, I completed a post-doctoral fellowship in clinical proteomics at Mount Sinai Hospital and the University of Toronto. In November 2018, I was appointed as an Assistant Professor and a Principal Investigator (first independent academic appointment) at the Department of Laboratory Medicine and Pathology at the University of Alberta. My current interests include clinical proteomics, mass spectrometry, prostate cancer, and biomarker discovery.

I am a graduate student at the University of Minnesota in the department of Biochemistry, Molecular Biology, and Biophysics under the mentorship of Dr. Stefani Thomas. My initial project is focused on a mass-spectrometry based approach to evaluate the utility of HDAC and PARP inhibitors in ovarian cancer treatment with an emphasis on determining how epigenetic modifications confer treatment sensitivity in the context of homologous recombination proficiency or deficiency. Overall, I believe my current research plan will support the development of biomedical breakthroughs improving treatment opportunities for patients with this lethal gynecological malignancy.

Merran is a PhD student with Prof. Randy Mrsny at the University of Bath, UK. Her current research interest focuses on the role of bioactive lipids in the promotion and resolution of inflammation in Inflammatory Bowel Disease.

Merran obtained a Master of Pharmacy degree at the University of Bath (2017) and completed her pharmacy pre-registration training with AstraZeneca (2018).

Erica Fatica is the Technical Director of Chemistry and Toxicology at the University of Cincinnati Medical Center and Assistant Professor in the Department of Pathology and Laboratory Medicine at the University of Cincinnati. She received her PhD in Clinical-Bioanalytical Chemistry from Cleveland State University and then completed a Clinical Chemistry Fellowship at Mayo Clinic. Her interests include test utilization, toxicology, endocrinology, and data science

Sina received his bachelor's degree in chemistry from the Sharif University of Technology, which is the most prestigious university in Iran. To pursue his scientific life as an analytical chemist, he joined the University of Florida. He is currently a Ph.D. student under the supervision of Prof. Richard Yost and Dr. Timothy Garrett. His research now focuses on finding biomarkers and understanding lipid profiles in pancreatic cells and exosomes by implementing UHPLC-HRMS. He utilized IE-omics and multivariate statistical analysis to characterize the major lipids in pancreatic cancer cells and particles.

I'm currently a second-year graduate student in the Hines lab at the University of Georgia. My focus now is looking into lipid composition variability caused by external growth factors or gene mutation using reversed-phase liquid chromatography mass spectrometry.

Deborah French Ph.D., DABCC (CC, TC) is currently Assistant Director of Chemistry and Director of Mass Spectrometry at the University of California San Francisco Clinical Laboratories. Her work currently focuses on the development and validation of LC-MS/MS assays for small molecules, specifically therapeutic drug monitoring, steroid hormones and toxicology. Deborah received her Ph.D. in biochemistry from the University of Strathclyde in Glasgow, Scotland and then completed a postdoctoral fellowship at St. Jude Children’s Research Hospital in Memphis, TN. She subsequently completed a ComACC Clinical Chemistry postdoctoral fellowship under the direction of Dr Alan Wu at the University of California San Francisco and is now board certified in Clinical Chemistry and Toxicological Chemistry by the American Board of Clinical Chemistry.

I am currently the director of Biochemical genetics and Special chemistry lab, LeBonheur Children's Hospital, and Associate professor at University of Tennessee Health Science Center. I am Board certified clinical biochemical geneticist by American Board of Medical Genetics and Genomics, a fellow of American College of Medical Genetics. I am also certified as specialist in chemistry by American Society of Clinical Pathology. My primary interests are diagnosis and treatment of Inborn Errors of Metabolism. I am also very interested in leading a team developing and implementing mass spectrometry-based testing in clinical lab.

My background is half clinician/half basic researcher, with passions that lie in the areas of solid organ transplantation and drugs of abuse. I worked in the Emergency Department and as an EMS provider for a decade before and during graduate school. My master's degree thesis critically examined the opiate prescribing practices of ED physicians. My PhD research focused on cellular mechanisms of hypothermic ischemia-reperfusion injury in the liver during the preservation period during transport prior to transplantation.

I knew within a week of beginning my clinical chemistry fellowship at the Mayo Clinic that I'd found the perfect fit - a field that combines clinical and research medical sciences to best serve our patients.

I've learned the diverse utility of mass spectrometry during fellowship and am excited to be part of a community that innovates this technology across the country.

Currently a PhD candidate, at Imperial College London, specialising in the metabolomic and microbiomic stratification of Inflammatory Bowel Disease (IBD) patients (both Crohn's and Ulcerative Colitis). Some of my skills include biological/clinical sample preparation and analysis using LC-MS, GC-MS, and proton NMR, and the processing of metabolomic data following acquisition. I have a personal interest in scientific writing and communication.

Devanjith Ganepola is a recent graduate from McMaster University in 2020 where he received his B.Sc (Honours) in Chemical Biology. The scope of his undergraduate thesis involved functionalizing graphite-based chemiresistive sensors for nitrate ion detection in aqueous media. Pursuing his passion for chemistry and its application in a medical setting, he will be continuing as a Masters candidate in the Medical Sciences Program at McMaster University where he will be adapting existing GC-MS methods to APGC-MS to determine inborn errors in metabolism of newborn patients.

Roland started as a microbiologist where he gained method development expertise using LC-MS. At the University of Tennessee Center for Biomarker Analysis he worked on lipid biomarker analysis using LC-MS/MS and GC-MS systems, including evaluating lipids in breath condensates. In 2006, he joined a leading MS instrument provider as an Application Specialist. In 2009, he joined a company providing laboratory automation systems where he led technology feasibility and development projects for innovative extraction consumables and workflows for the clinical MS lab. In 2015, Roland joined the clinical chemistry department of the University Hospital Bern in Switzerland to gain insights into the feasibility of approaches and concepts in the clinic. Since 2017, he has been working as Business Development Manager for a large life science company in the area of Clinical MS automation. Roland has been attending MSACL since 2010 with the goal of extending the use of LC-MS diagnostic applications into the clinical lab.

Bryan is an assistant professor at Wageningen University working on the understanding of the pathophysiology and long-term metabolic consequences of child malnutrition.

I joined Murdoch University in 2019 as a Senior Lecturer in Phenomics based at the Australian National Phenome Centre (ANPC), specialising in diabetes and obesity. I received my BSc(Hons) in Biomedical Sciences in 2005 from the University of Newcastle, UK, followed by my MSc in Forensic Science at King’s College London in 2008. I completed my PhD at the same institution in analytical chemistry, in particular liquid chromatography and mass spectrometry, for the detection of doping agents in sport.

I have worked for instrument manufacturers (Waters Corporation and Shimadzu UK Ltd) as well as in academia (Imperial College London and the University of Reading, UK). My research interests are in the application of chromatography and mass spectrometry for metabolic phenotyping to investigate the interactions between our genes and environment in terms of disease risk. I am particularly interested in the influence of lifestyle factors such as diet and exercise in health and disease, and the role of the microbiome.

My expertise are in analytical chemistry and metabolomics and I have taught into a range of undergraduate and postgraduate courses on these topics, as well as delivering hands-on training in these areas.

Peter joined Waters Corporation in 2005 as an Executive Clinical/Forensic Specialist. At Waters, Peter is responsible for interfacing with both clinical and forensic labs and developing the LC-MS business in those market segments with the regional sales teams. Prior to Waters, Peter held various positions as Senior Mass Spectrometry Sales Specialist at Bruker Daltonics, SFC-MS Business Development Manager at Berger Instruments, and Senior Applications Consultant for LC-MS at Agilent Technologies. Before moving to the scientific instrument segment, Peter worked in the pharmaceutical industry as a Senior Research Investigator for Sterling Pharmaceuticals and a Post-Doctoral Scientist at SmithKline focusing mainly on protein drug targets and protein-based biopharmaceuticals.
Over the years, Peter has developed numerous hyphenated mass spec methods for analysis of pharmaceuticals and drugs of abuse, protein/peptide drugs, polymers, and small molecule metabolites. Other accomplishments include the development of the first commercially available SFC-MS system. Peter has delivered many LC-MS training courses and has given poster and oral presentations at numerous scientific meetings.

Dr. Zane Hauck is the Assistant Laboratory Director and Research Scientist at ZRT Laboratory. In this role, Dr. Hauck ensures the highest quality and accuracy for all samples run through ZRT and develops new laboratory tests to allow providers access a much broader depth of individualized profiles to aid them in their assessment of health and disease. Dr. Hauck is an educator for ZRT and communicates the importance of laboratory testing and its usefulness to providers and the general public through speaking engagements, posters, and blogs.
Dr. Hauck began working at ZRT in March 2019 after spending 2 years in the dietary supplement industry as a formulator and quality manager. He received his PhD in Pharmacognosy from the University of Illinois at Chicago under the tutelage of Dr. Richard van Breemen in 2017.

Amber is VP of MSACL and co-founder and developer of BadgerScan. Amber earned a BS in Computer Science at the University of California, San Diego. Post-graduation, Amber was involved in a startup company developing computer vision algorithms. After the wee company was purchased by a proper non-startup company, Amber spent eight years practicing the development of proper-production-quality code. This was followed by five years at The Scripps Research Institute in an Electron Microscopy lab. A side project developing the BadgerScan lead collection App pulled Amber into the MSACL community.

CURRENT COMMITTEE WORK
2019 - Present Elected board member Nordic Metabolomics Society; Early-career representative
2018 - Present Elected Committee Member Early-career Member Network of the Metabolomics Society
2018 - Present Steering board member National Junior Faculty (as well as member of local committees at University of employment)

WORK EXPERIENCE
2019 - Present Postdoctoral Fellow (Novo Nordisk Fellowship programme), Karolinska Institute, Sweden
2017-2019 Postdoctoral researcher, Lund University Diabetes Center, Center for Analysis and Synthesis, Sweden

EDUCATION
2017 PhD in Biomedicine (Marie Curie ITN Fellow), Laboratory Genetic Metabolic Diseases, Academic Medical Center Amsterdam, The Netherlands
2013 MSc Molecular Bioscience - University of Southern Denmark, Denmark
2011 BSc Nutrition Sciences - Christian-Albrechts-University, Germany

I am currently a Postdoctoral Research Associate at the department of Clinical Neurosciences, University of Calgary. I received both Bachelors and Master's degree in Anatomy from the University of Ilorin, Nigeria.
I am interested in undergoing the clinical chemistry fellowship.

Ólöf Gerður is a PhD student at Margret Thorsteinsdottir´s and Sigridur Klara Bodvarsdottir lab in Iceland. She is working on a collaborative project with Zoltan Takat´s lab at Imperial College London where she uses imaging mass spectrometry to identify biomarkers in breast tissue. Ólöf obtained her B.Sc. at University of Iceland in Biochemistry with focus on molecular biology. She achieved her M.Sc. at University of Copenhagen (Denmark) in Human Biology, with focus on cellular and molecular biology. She has 3 years experience working as a research assistant for both University of Iceland and University of Copenhagen as well as she did a short-term internship at the Danish pharmaceutical company, Lundbeck.
Ólöf is a current co-Chair of the MSACL Early Career Network (MSACL ECN).

Postdoctoral research fellow at Mayo Clinic

Dr. Chris Koch is the Director of Chemistry at the Sanford Laboratories reference lab in Sioux Falls, South Dakota. He is currently developing a clinical mass spectrometry program with an initial focus on clinical toxicology. He is also actively involved in teaching Clinical Chemistry in the University of South Dakota Pathology Residency program at the Sanford Health Sioux Falls Medical Center.

Dr. Koch worked for nearly a decade as a Clinical Laboratory Technician and Development Technician in the Hospital Clinical Laboratories of the Mayo Clinic in Rochester, Minnesota, where he first developed a passion for laboratory medicine. He received his PhD in Clinical-Bioanalytical Chemistry from Cleveland State University and performed his dissertation research at the Cleveland Clinic Lerner Research Institute. He completed his fellowship training in Clinical Chemistry at Yale-New Haven Health and is board certified in clinical chemistry.

Research in the Koomen Laboratory focuses on analytical chemistry development, elucidation of biological processes, and implementation of clinical assays using proteomics, metabolomics, and quantitative mass spectrometry. Much of this work is performed using liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM). We have developed a 97 protein panel that is being applied to prescreening, selection of therapy, and matching to clinical trials. We are evaluating cancer signaling proteins, immune cell markers, and other biomarkers in the context of the tumor phenotype using this highly multiplexed approach. In multiple myeloma, this technique is being applied to develop novel strategies to evaluate tumor burden. Current clinical assays use gel or capillary electrophoresis to measure the antibody secreted by the myeloma, which is used to stage the patients and estimate tumor burden. Quantitative mass spectrometry should be significantly more sensitive at detecting and quantifying these antibodies. Improvements in the analytical technique would lead to earlier detection of disease relapse, more rapid intervention with second line therapies, and potentially improved patient outcomes. These projects share the common goal of changing the standard of patient assessment and care using mass spectrometry.

My name is Daniel Kratz and I'm currently in the last phase of my Ph.D. (3rd year) at the Institute of Clinical Pharmacology at the University Hospital of the Goethe-University, Frankfurt. I'm a trained pharmacist but decided to go back to university because I like to get to the bottom of things and enjoy developing and optimizing processes. I now work in the field of analytical chemistry to improve detection limits of small molecules (lipids and lipid mediators) in biological matrices using µLC-MS and to examine critical factors during sample generation (pre-analytical research). I enjoy data visualization and creation of vector graphics to communicate my research which also helps me with my private projects using my pen plotter.

Cyrille Lamboley has a Master Degree in Analytical Chemistry and has been working in the field of Liquid Chromatography and Sample Preparation for more than 15 years. After working several years for Waters and Biotage, he has joined Restek in 2018 as LC & Sample Prep Specialist.

My name is Nicholas Larkey and I am currently a 2nd-year Clinical Chemistry Fellow at Mayo Clinic.

Dr. Liao has more than ten years of clinical and management experience in the laboratory medicine and newborn screening center. She was a Medical Laboratory Scientist who trained in Taiwan. After obtaining her PhD in Clinical Medicine, she completed postdoctoral fellowship training in Clinical Chemistry at the University of Washington and Seattle Children Hospital. She is board certified as a Clinical Chemist by both the American Board of Clinical Chemistry and National Registry of Certified Chemists. She continues to focus on translation of the analytical power of mass spectrometry to real clinical applications.

My trajectory has been within the academic environment and I am passionate about teaching and learning, as well as learning and teaching. Through my scientific journey, I realized that people are the focus of my work. Through encouragement and guidance, people can do a lot for our world through science. That's why I became a teacher! As a young professor in Brazil, the challenges are enormous for science. I hope to make good international partnerships and collaborate with Brazilian students, in order to transform, even a little, Brazil's faith and enlightenment in science, in addition to contribute to the development of my country.

Y. Ruben Luo, PhD, DABCC is an assistant professor of pathology at Stanford University and associate director of clinical chemistry laboratory at Stanford Health Care. He is dedicated to the innovation of clinical diagnostic technologies, and has pioneered the application of label-free immunoassays and top-down mass spectrometry in clinical chemistry. He completed his clinical chemistry fellowship at University of California San Francisco. Before the fellowship, he worked in the clinical diagnostic industry holding multiple managerial positions. He received his PhD in chemistry from Stanford University, and BS from Peking University.

I obtained my degree of Biochemist in 2010 and my Ph.D diploma in cancer biology in 2016 at the School of Pharmacy and Biochemistry of the University of Buenos Aires, Argentina. In 2016, I obtained a postdoctoral position at the Centro de Investigaciones en Bionanociencias (CIBION) of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), a national reference laboratory for MS-based metabolomics studies, with the mentorship of Dr. María Eugenia Monged. In particular, I applied UPLC-QTOF-MS coupled with multivariate analysis to profile the metabolome and the lipidome of human serum samples as well as in vitro models to discover clear cell renal cell carcinoma biomarkers. Moreover, I had the opportunity to work as a part of multiple collaborative projects in a Marie Skłodowska-Curie Actions (MSCA) Research and Innovation Staff Exchange (RISE), MARSU Project: “MARine atmospheric Science Unravelled: analytical and mass spectrometric techniques development and application”, performing seawater omics studies applying DART-MS. In 2019, I participated in the 4th International School of Mass Spectrometry (Spain) and obtained an award for the best oral presentation. During 2017-2019, I participated as a teaching assistant in 3 international courses that focused in metabolomics. In 2020, I got a permanent position as a career researcher at the Instituto Nacional de Tecnología Industrial (Argentina), to work in the Laboratory of Dr. María Julieta Comin. I am in charge of expanding the MS capabilities in the Chemical Department and to perform pharmacometabolomics studies to contribute to the development of new compounds for disease treatment. I will be able to expand the acquired knowledge in MS-based metabolomics for new ideas to address healthcare issues in the region. In 2016 I became a member of the Argentinian Mass Spectrometry Society. I have been a teaching assistant for Advanced Biological Chemistry at the School of Pharmacy and Biochemistry of the University of Buenos Aires for last 10 years, allowing me to keep in touch with young students and to participate of the teaching-learning process within the framework of biochemistry, molecular and cell biology. (ORCID: 0000-0002-1709-0685)

I am a professor of Analytical Biochemistry in the Ryerson Analytica Biochemistry Laboratory (RABL). I focus on the extracellular or circulating protein ligands in the blood and their receptors on the surface of cells. I use the combination of enzymatic, biochemical, immunological, molecular, mass spectrometric and laser confocal microscopic methods to analyze blood proteins or peptides and their receptors on cells. Cell receptors were ligated, activated and captured using ligand micro beads for LC-ESI-MS/MS and laser confocal analysis with receptor function assays testing drugs and siRNA or dominant negative mutants. Blood proteins and peptides, or secreted proteins, were compared between serum or plasma samples from normal, controls and diseases, developmental stages, or cells lines. Our lab uses SQL/R database and statistical analysis of proteomic results from large scale LC-ESI-MS/MS experiments. We invented the ultra sensitive ELIMSA system for linear quantification of pico to femto gram amounts of proteins, ligands or nucleic acids that can accurately quantify a single alkaline phosphatase-streptavidin (APSA) enzyme conjugate.

I am a first year clinical chemistry fellow at the University of North Carolina, Chapel Hill, NC. I'm originally from upstate New York (New York City’s park), where terms like “lake effect snow” and “garbage plates” are commonplace in conversation. I completed my graduate studies at the University of Rochester, Rochester, NY in Pathology where I validated a locus uncovered by human genome-wide association studies on a gene no one has heard of (but take my word for it, it was a really cool gene). Since then, I am a recovering PhD student/Instructor and enjoying every day of clinical laboratory testing. My goal for this year is to level up from a “Non-existent” mass spectrometry experience level to “Low/Medium” experience. I am taking it one day at a time, and I am loving it.

Current Research Interest
Experimental, basic science, clinical and epidemiological studies relating to aspects of insulin resistance, the metabolic syndrome and cardiovascular risks in patients with diabetes and metabolic disease. Current research projects include;
• Discovery and validation of oxidative stress biomarker panels in patients with diabetes and cardiovascular disease.
• Clinical trials, pharmaco-interventional studies to identify novel therapeutic target for diabetes and cardiovascular disease.

The primary focus of my research is working with physicians and scientists to solve complex problems in pediatric drug development. Our laboratory is equipped with UPLC-MS/MS and UHPLC-MS/MS systems and Watson LIMS. We specialize in the development and validation of analytical methods and their implementation for pediatric and adult clinical sample analysis. Our clinical research is focused on the pharmacokinetic analysis of dexmedetomidine, midazolam, morphine, ketamine, cefepime, cefazolin, voriconazole, efavirenz, tenofovir, vancomycin, and cannabinoids. We also have expertise in the fast assay development for preclinical studies in various biological matrices. Our preclinical research involves the pharmacokinetic analysis of treprostinil, oxycodone, SN-38, irinotecan, vemurafenib, and tamoxifen. In addition, I contribute to building a biorepository for samples from critically ill children. We continue to evaluate and utilize new tools and microsampling technologies to facilitate preclinical, translational, and clinical research.

Mass spectrometric researcher with 9 years experience in clinical pharmacokinetics and metabolomics.

Zhixu Ni is a postdoc researcher at the Fedorova research group. Originally coming from analytical chemistry background (MSc, Leipzig University, Germany), Zhixu Ni transitioned to data analysis and software development during his PhD study on MS based lipidomics. Zhixu Ni’s main research interest is the dysregulation of enzymatically and non-enzymatically modified lipidome and metabolome in metabolic disorders with a strong focus on the high throughput LC-MS lipidomics data analysis and integration of multi-omics data. He is the main developer of several open source lipidomics tools including LipidHunter2, LPPtiger, LipidCircos, and LipidLynxX.

I obtained my PhD from University of Greifswald, Germany in Cardiovascular proteomics where I studied proteomic differences in chronic stages of dilated cardiomyopathy in mice models. Subsequently I worked in industry and in research lab as protein mass spectrometrist. I am currently working as a research associate in glycoproteomics at the Dept. of Molecular Sciences, Macquarie University. My research interests are method development in mass spectrometry and it's applications in Proteomics

Sarah Noll is currently pursuing a Ph.D. in chemistry at Stanford University with Professor Richard N. Zare. Her research is focused on clinical and biological applications of DESI-MSI. Sarah graduated from Pomona College with a B.A. in both chemistry and German studies. Following graduation, she spent a year studying catalytic inorganic nanoparticles at the Johannes Gutenberg University in Mainz, Germany on a Fulbright grant. She then obtained her MPhil in Chemistry at the University of Cambridge, using Raman spectroscopy to non-invasively identify sub-surface pigments in works of art. Outside of research, Sarah is actively involved in undergraduate education and outreach, as well as young women’s leadership development. She also works as a student museum guide at the Cantor Arts Center and the Anderson Collection on the Stanford campus.

I am currently a PhD student at the University of Cape Town. I also have an MSc degree in bioinformatics.

Lily is a Clinical Chemistry Fellow at the Baylor College of Medicine and Texas Children Hospital in Houston, Texas. She received her Ph.D. in Medical Science from the Hull York Medical School in England. During her graduate research, she applied proteomics to identify novel drug targets and biomarkers for Malignant Pleural Mesothelioma. She also served as a Medical Laboratory Scientist at the Clinical Biochemistry department of the NHS lab in Hull from 2013 to 2016. Her current interests include Laboratory stewardship, biomarker discovery, and the development of accurate and cost-saving laboratory tests.

Dr Zach Pang is a research fellow at the GlycoAnalytics group, Bioprocessing Technology Institute, A*STAR Singapore. His research focuses on the glycomic and glycoproteomic of biologics. He obtained his PhD from the Department of Bioengineering, Imperial College London under the A*STAR Graduate Scholarship. His PhD study focused on the role of haemodynamic wall shear stress and LRG1 in cardiovascular diseases.

Dr Robert Plumb is the Director of Omics and Small Molecule Pharma in the Waters Scientific Operations Division, based in Milford, Massachusetts.

Dr Plumb has published over 100 papers on the subject of HPLC/MS and NMR for bioanalysis, metabolomics and metabolite identification. He is a recognized expert in the use of liquid chromatography with mass spectrometry, capillary scale LC, purifications scale LC and metabonomics, giving many invited papers at international meetings around the world.

After obtaining an honors degree in Chemistry from the University of Hertfordshire in 1992, he started work in at Glaxo Research and Development Drug Metabolism Department. During his time at Glaxo and later GlaxoWellcome he continued his research in liquid chromatography combined with NMR and mass spectrometry for metabolite identification and bioanalysis obtaining his PhD in 1999. Dr Plumb continued his work for GlaxoWellcome with the responsibility of metabolite identification using HPLC/MS/NMR and new analytical technology development. In 2001 he moved to Waters Corporation in Milford, MA, USA where he was responsible for the Life Science Chromatography group and latterly LC/MS applications in the Pharmaceutical Market Development Group before becoming the Director of Metabolic Phenotyping in 2013 and the Director of Omics and Small molecule Pharma in the Scientific Operations Division in 2017. He has been awarded several visiting Professorships including visiting Professor in at Kings College London, visiting Professor at Imperial College in the Dept Surgery and Cancer, Visit Professor at Murdoch University and a Fellow of the Royal Society of Chemistry. In 2014 he was awarded Highly Cited Researcher by Thompson Reuters.

I am a postdoctoral research associate at University of Nebraska-Lincoln. Currently I am working on targeted method development for detection and quantification of proteins in foods which can trigger an allergic response in susceptible individuals. Considering the complexity of food matrices and the type of processing these foods have undergone, I equate my project to solving a multi-level puzzle with increasing challenges to overcome at each level. I am fascinated by the technology behind mass spectrometry and its applications, especially in field of proteomics. So far in my career I got opportunities to employ mass spectrometry and proteomics to address challenges in food allergy, cell biology, infectious disease biology, cancer biology, and bacterial strain improvement. I believe mastering in the art of mass spectrometry will open a path to apply one’s expertise in various areas, from academia to industry, from clinical labs to pharmaceutical manufacturing. I am expecting to transition out of my current postdoctoral position towards the second half of 2021. I would like to transition into a job where I can combine my passion for mass spectrometry, proteomics, and method development. I could see myself fitting well in the role of an R&D scientist in instrumentation industry, in clinical proteomics labs, or in biopharmaceutical industry. I am looking for opportunities to netwrok with people from these areas.

Ivayla Roberts is a doctoral researcher at the University of Liverpool in Prof. Kell system biology group. Originally coming from computer science background (MSc, Montpellier France) Iva transitioned to molecular biology research via a Translational Molecular Medicine MRes (Manchester, UK).
Iva’s research interests are metabolomics, mass-spectrometry, and the application of statistical and machine learning computational approaches to metabolomics.
Iva’s PhD is focused on metabolomics in COVID-19.

Hoda Safari Yazd is a Ph.D. candidate in analytical chemistry at the University of Florida and working under the supervision of Prof. Richard Yost and Dr. Timothy Garrett. She received her B.Sc. in chemistry from Sharif University of Technology in 2015 and her M.Sc. in computational chemistry from the same school in 2017. Hoda's research at UF primarily focuses on combining analytical chemistry tools and scientific programming for the metabolomic discovery of rare disorders. She is currently working on two projects; the first project concentrates on the detection of new biomarkers in meningiomas to improve early detection of this disease by employing machine learning as a tool on mass spectrometry-based metabolomics data. The second project is focused on the characterization of rare X-chromosome deletion disorders using metabolomics and lipidomics workflows by UHPLC-HRMS on neural progenitor cells. Hoda is one of the founding members and main organizers of the MSACL Early Career Network (MSACL-ECN).

I am a clinical chemistry fellow in Dept. of Pathology and Laboratory Medicine at UCLA.

Emily Sekera earned her B.S. in chemistry at Rochester Institute of Technology in 2015. She then completed her graduate studies in analytical chemistry at University at Buffalo, in the laboratory of Prof. Troy D. Wood studying disease states using -omics based techniques and high resolution mass spectrometry. She is currently a postdoctoral researcher working under Dr. Amanda B. Hummon investigating at the intersection of cancer biology and analytical chemistry.

I received my Bachelor of Science degree in Biology from Bloomsburg University with a minor in chemistry in 2009 and my Doctor of Philosophy degree in Biomedical Sciences from the Medical University of South Carolina (MUSC) in 2014. I completed a two-year postdoctoral fellowship at MUSC in the Nephrology proteomics laboratory where I focused on learning tandem mass spectrometry and discovery of protein biomarkers for metabolic syndrome in bottlenose dolphins. I successfully completed an ABCC certified Clinical Chemistry Fellowship at the University of California, San Diego and an active member of AACC, ASMS, AACR, NRCC and MSACL.
During my postdoctoral research I learned the fundamentals of mass spectrometry assay development and validated a multiple reaction monitoring mass spectrometry assay for the measurement of clinically relevant peptide modifications in serum samples. As a Clinical Chemistry Fellow at UCSD my research focused on developing a LC-MS/MS assay for marijuana markers indicating recent use in oral fluid, whole blood, and breath to be used in a study for establishing the driving impairment limit. I was also involved in identifying drugs via broad screen urine analysis using all-ion tandem mass spectrometry.
Currently I am the Clinical Biochemist at Santa Clara Valley Medical Center where my responsibilities are overseeing Chemistry, Special Chemistry, and Toxicology. I am actively involved in clinical service and currently mentor future clinical laboratory scientists at San Jose State University.

Devin J. Swiner currently is a 5th year, PhD candidate working under Dr. Abraham Badu-Tawiah at The Ohio State University. Since graduating from The University of Pittsburgh in 2016 with her B.S. in Chemistry, her current research is focused on developing a new ionization source for mass spectrometry using cellulose materials for applications in clinical diagnostics. At OSU, she serves as Chapter President of the National Organization for the Professional Advancement of Black Chemists and Chemical Engineers (NOBCChE) and as Vice President for the Black Graduate and Professional Student Caucus. In these capacities, she is able to mentor students as they grow and develop during their programs, an effort that awarded her The Susan M. Hartmann Mentoring and Leadership Award in 2018. In her free time, she also co-runs a blog, #MacScientist, whose goal is to increase representation of black women in STEM fields, and more recently co-founded a #BlackInChem Twitter campaign, to amplify and celebrate Black chemists. Her advocacy work is documented on her professional website, Devinthechemist.com.

Akash Talukder joined as a Ph.D. student (Proteomics and Bio-Analytical Mass Spectrometry Research Group) in the Department of Chemistry and Biochemistry at the University of Texas at Arlington in August of 2019. He received his B.Sc (honors) and M.Sc degree in Chemistry from the University of Dhaka, Dhaka, Bangladesh.

Professor in Pharmaceutical Analytical Chemistry at the Faculty of Pharmaceutical Sciences, University of Iceland and R&D Director of ArcticMass LTd, Reykjavik, Iceland. Dr. Thorsteinsdóttir received her PhD from Uppsala University, Sweden in 1998. From 2000 to 2009 she was the managing director of Bioanalytical Laboratories at deCODE Genetics, Reykjavik, Iceland. She has extensive experience in development of analytical methods for metabolite profiling and quantification of clinical biomarkers in various biofluids utilizing chemometrics with the goal of improved clinical management of patients towards personalized patient care.
Her current research interest includes studies of lipid metabolism in cancer cells and profiling plasma derived biomarkers for early detection of BRCA-related breast cancer. She is responsible for implementation of clinical mass spectrometry for support of diagnostics and therapeutic drug monitoring in collaboration with ArcticMass and the Landspitali University Hospital, Reykjavik, Iceland with major focus on quantitative targeted proteomics for clinical diagnosis. She is a principal investigator of the Icelandic Research Rannis projects, profiling metabolites for breast cancer diagnosis and search for novel biomarkers for early breast cancer diagnosis by metabolomics. Dr. Thorsteinsdóttir is a principal investigator for the Marine Biotechnology ERA-net project CYNOBESITY and the Horizon 2020 project MossTech, with the main task to isolate, identify and structurally characterize bioactive compounds from cyanobacteria, Icelandic mosses and liverworts. She is one of the founders of Females in Mass Spectrometry (FeMS), she is a vice-leader of the working group clinical significance and applications of (epi)lipidomics in the pan-European network, EpiLipidNET and vice-chair of the Nordic Metabolomics Society.

Unaiza Uzair earned her Doctorate in Chemistry from Clemson University in 2020 and currently she is working as an Analytical Chemist at the South Carolina Public Health Lab to develop methods for the opioids biosurveillance program. Dr. Uzair is passionate about lab to market research geared towards biomedical and biosurveillance applications. Her PhD research was focused on the development of an imaging technique (XELCI) and a pH sensor to detect and monitor implant associated infection. She worked on instrumentation development of a luminescence imaging system for noninvasive imaging of surface specific changes and as a noninvasive surface characterization technique. Dr. Uzair has a background in forensic science and quality control analysis, and is well versed in research design, data collection, analysis, and laboratory operations.

In 2017 I started my PhD research at the departments Clinical Chemistry and Laboratory Medicine at the Leiden University Medical Center. Our research group develops LC-MRM-MS-based methods for protein quantitation in body fluids for clinical applications and, ultimately, routine patient care. My current research aims to improve the timely diagnosis of kidney injury using a multiplex proteomic test.

Translation of emering analytical strategies towards the clinical laboratory is my primary research interest. This includes non-invasive strategies such as cell-free DNA quantitation and multiplex mass spectrometry for marker quantitation in body fluids.

Prior to joining the group of prof. C.M. Cobbaert, I received training as a master student at the departments Pharmacy, Pharmacology and Clinical Chemistry of the Dutch Cancer Institute and the Medicinal Chemistry department of the Leiden Academic Centre of Drug Research.

Greetings! I have 30 years in classic sales and marketing with 16 years in IVD Medical Device marketing including the launch of novel Clinical LCMS systems globally. Now as a consultant beyond the traditional Life Sciences supplier realm, my passion is to help people be more relevant in communications and collaboration to advance healthcare. This is done primarily through professional development and mentoring of individuals, teams or entire institutions.

Let's connect on Linked In. I'm happy to share my perspective and experiences with you.

Mudita is a PhD student at M4i, Maastricht University supervised by Ron M.A Heeren and Berta Cillero Pastor. She is a Marie Curie fellow working on FoodTraNet project where she is studying the influence of crop protection and soil nutrients on the molecular composition of grape vine leaves by comparing the metabolic differences before and after spraying (commercial versus biological spraying).
This work involves the use of DESI, MALDI-ToF, MALDI Biotyper, REIMS and LC-ESI-MS.

Anita graduated with her Bachelors of Science in Chemistry from Texas A&M University where she worked on the optimization of ion emission for the enhanced performance of Time-of-Flight-Secondary Ion Mass Spectrometry. Following her passion for mass spectrometry, she continued her education at the University of California Davis under the supervision of Carlito Lebrilla. Here, Anita lead several mass spectrometry-based projects involving glycomic, proteomic, and glycoproteomic analysis of various biological samples including cells, feces, breast milk, serum and amniotic fluid. Anita is expecting to graduate with her PhD this year (2022) to pursue a position in bio-analytical chemistry.

I am a 3rd year PhD student on the Precision Medicine DTP at the University of Edinburgh. My current research focuses on development and application of novel bio-analytical MS technologies (ion mobility and imaging) for the separation, detection and identification of small molecule metabolites involved in disease processes. This work is accompanied by handling large 3D data-sets for use in conjunction with other imaging modalities (e.g. histology). I am also interested in the development of derivatisation techniques and procedures for application in chromatographic and MS-based research. All of this work involves the integration of laboratory-based in vivo skills, bioinformatics, programming and multivariate analysis, for the development of better diagnostic and analytical techniques.

My name is Ruhan Wei, and I am a first-year Clinical Biochemistry Fellow at Cleveland Clinic.

Ashley Woolfork is a first year Institutional Research and Academic Career Development Awards (IRACDA) fellow at the University of Pennsylvania in the department of Systems Pharmacology and Translational Therapeutics. Her research uses mass spectrometry imaging to understand systems level changes in metabolism as it relates to sleep and circadian rhythms.

I am currently a clinical chemistry fellow training under Drs. Amy Saenger and Fred Apple at Hennepin County Medical Center/Hennepin Healthcare in Minneapolis, MN. My current research projects involve (1) developing a LC-MS/MS method for quantification of a panel of anti-epileptic drugs and (2) validating the analytical and clinical characteristics of a novel high-sensitivity cardiac troponin I point-of-care assay.

Ethan Yang is a postdoctoral fellow in Prof. Kristine Glunde's Lab in the Department of Radiology at Johns Hopkins University. His current research focuses on combining imaging mass spectrometry with other biomedical imaging approaches to provide a more holistic approach to reserach and diagnosis. He completed his PhD under Prof. Pierre Chaurand at the University of Montreal working on elaborating new techniques to enhance the sensitivity and selectivity of MALDI-TOF imaging mass spectrometry. He obtained his B.Sc. in Biochemistry at McGill University. He is a founding member of the MSACL Early Career Network (MSACL ECN) and is now the interim Chair of the Asia-Pacific Region.

Dr. Yost is the University Professor and Head of Analytical Chemistry at the University of Florida. He is also director of the Southeast Center for Integrated Metabolomics (SECIM) and of NIH’s Metabolomics Consortium Coordinating Center (M3C). He is recognized internationally as a leader in the field of analytical chemistry, particularly tandem mass spectrometry (MS/MS). His research has been recognized with the ASMS Award for Distinguished Contribution in Mass Spectrometry, the MSACL Award for Distinguished Contribution to Clinical Mass Spectrometry, and the Florida Academy of Sciences Medal. Dr. Yost currently serves as President of the American Society for Mass Spectrometry (ASMS).

After graduated from undergraduate school, has worked nearly 11 years in mass spectrometry based proteomics, as an application scientist. Now moving to data science and focusing on mass spectrometry data processing and mining in the area of clinical diagnosis.

I am a bioanalytical chemist with more than 10 years's mass spectrometry experience. My research focuses on application novel ion mobility-mass spectrometry technique to multi-omics to understand important disease state and clinical applications.